EXHIBIT 99.1

# 

| |  | NEWS RELEASE
| |  | ------------

|For Release:
Thursday, January 26, 2006, 3:05 pm Central Time |  | Contact: Howard Root, CEO
James Hennen, CFO
Vascular Solutions, Inc.
(763) 656-4300
|------------------------------------------------------------- |  | -----------------------------------------------------------------------------------

# VASCULAR SOLUTIONS
ANNOUNCES RECORD FOURTH QUARTER RESULTS

Net sales increase
32% from Q4 of 2004 to record $8.9 million.

MINNEAPOLIS, Minnesota
 Vascular Solutions, Inc. (Nasdaq:VASC) today announced its eighth consecutive
quarterly net sales record in its results for the fourth quarter ended December 31, 2005.

Net
sales during the fourth quarter were $8,859,000, an increase of 32% from net sales of
$6,706,000 in the fourth quarter of 2004. The primary contributors to the increase in
sales were broad annual growth in the companys D-Stat Dry, Pronto and Vari-Lase
product lines. In total, over 84% of net sales in the fourth quarter came from sales of
five new product lines that Vascular Solutions has launched in the U.S. since 2003.

The
resulting net loss for the fourth quarter was $407,000 or $0.03 per share, improving from
a net loss of $573,000 or $0.04 per share in the fourth quarter of 2004. During the fourth
quarter of 2005 the company incurred $563,000 in expenses related to the development and
qualification of a new supply of thrombin, a primary component of its hemostatic products.
As adjusted (excluding the thrombin qualification expenses and assuming a tax rate of 40%)
net income was $93,000 or $0.01 per fully diluted share in the fourth quarter.

2005
was an excellent year for Vascular Solutions as we set a new sales record each quarter of
the year, commented Howard Root, Chief Executive Officer of Vascular Solutions.
For the year, we increased our net sales to over $32 million, an increase of 46%
from net sales of $22 million in 2004. For 2005 we also reported our first adjusted net
income of $636,000, or $0.04 per share, compared to an adjusted net loss of $3,298,000, or
$0.24 per share, in 2004. Building off this base, and with several new products and
product line improvements and extensions planned for launch starting in this first quarter
of 2006, we expect to continue to set new quarterly sales records each quarter for the
foreseeable future.

Net
sales of the D-Stat Dry product line were $3,625,000 during the fourth quarter, an
increase of 39% over the fourth quarter of 2004. A total of 499 accounts in the U.S.
purchased the D-Stat Dry in the fourth quarter, with a re-order rate of 72%.
Sequential growth in our D-Stat Dry business in the fourth quarter was negatively
affected by several bulk re-orders that we expected would occur in December but instead
were deferred into the first quarter of 2006, commented Mr. Root. We believe
that the resumption of these bulk orders and growing sales of our new ThrombiGel
configuration will result in continued increases in sales of the D-Stat Dry product line
throughout 2006.

---

Net
sales of the Pronto extraction catheter totaled $1,745,000 in the fourth quarter, an
increase of 60% over the fourth quarter of 2004 and 4% sequentially from the third
quarter. We have recently overcome our manufacturing ramp-up limitation on sales of
the new V3 version of the Pronto extraction catheter, and we are now able to actively
promote the new version, commented Mr. Root. Our sales force is excited about
the clinical outcomes they have witnessed with the limited launch of the V3 version in the
fourth quarter, and we are pleased that a manuscript documenting the excellent clinical
results of the Pronto in the DEAR-MI study has recently been accepted for publication in
the Journal of the American College of Cardiology. These developments result in our
continued expectation that the Pronto will be our fastest growing product line in
2006.

Net
sales of the Vari-Lase endovenous laser product line totaled $1,696,000 in the fourth
quarter, an increase of 55% over the fourth quarter of 2004 and 37% sequentially from the
third quarter. The fourth quarter demonstrated the competitive success of our sales
force in the endovenous laser therapy market, commented Mr. Root. Overcoming
aggressive competitive attacks, our direct sales force has used its size and clinical
skills to grow Vari-Lase sales and market share, a trend that we expect will continue
throughout 2006.

Net
sales of the Duett sealing device product line totaled $742,000 in the fourth quarter of
2005. We continue to support and harvest our Duett product line, and our
direct sales force has maintained our long-time Duett customers while this business has
continued to decline as forecasted, commented Mr. Root.

Net
sales of the D-Stat Flowable hemostat were $518,000 in the fourth quarter of 2005, an
increase of 33% over the fourth quarter of 2004. We expect the D-Stat Flowable to
continue to represent a substantial part of our business with its current indications for
use, commented Mr. Root. Driving future growth will be the pocket
protector indication of the Flowable for use in pacemaker and ICD implants which we
now expect to file with the FDA within the next week.

Overall
gross margin across all products was 70% in the fourth quarter of 2005, consistent with
the gross margin in the fourth quarter of 2004, but down 3% from the third quarter of
2005. The sequential gross margin decrease was principally due to increased sales of
Vari-Lase consoles and Vari-Lase disposable products in the fourth quarter, which have
relatively lower gross margins compared to the D-Stat Dry and Pronto products. Based on
projected increased sales of the new V3 version of the Pronto extraction catheter as well
as the inclusion of stock based compensation in 2006, gross margins for 2006 are expected
to range between 67% and 70%.

The
company also provided an update on its progress in the development and launch of new
interventional medical devices. During the first quarter of 2006 we expect to launch
the Twin-Pass and Skyway catheters  two specialty purpose catheters for
Interventional cardiology, commented Mr. Root. During the second half of 2006,
we expect to launch the GuideLiner, Gopher, and Micro-Introducer Catheter
products through our direct sales force to our existing Interventional cardiology and
Interventional radiology customers.

During
the fourth quarter, development and qualification of a new source of thrombin for use in
the companys hemostatic products also continued. We have finalized our
regulatory strategy and have taken delivery and accepted our initial three lots of
thrombin from our new thrombin manufacture partner. This receipt and acceptance clears our
initial manufacturing hurdle, which keeps us on track for the completion of our clinical
requirements before the end of 2006 for the approval of the use of the new thrombin in our
hemostatic devices by the second quarter of 2007, commented Mr. Root. In
addition, our yield on the initial three lots was better than forecasted, and we now
believe that the gross margin of our products utilizing our new thrombin will not
materially change from the gross margin of our products using thrombin from our former
source.

---

The
company also issued guidance for the first quarter and year 2006. Net sales for the first
quarter are expected to increase to between $9.2 million and $9.4 million. While
forecasting specific annual sales growth is difficult due to the multiple planned new
product introductions, sales for 2006 are expected to increase by at least 25% to between
$41 and $43 million. Longer term, net sales are expected to continue to increase by at
least 25% annually over the next several years. We continue to believe that this
strategy of internally developing a variety of new clinically-based products sold by our
focused direct sales force to our existing customers will allow us to achieve our next
long term milestone of $100 million in annual sales, concluded Mr. Root.

# Conference Call &
Webcast Information

Vascular
Solutions will host a live webcast starting at 3:30 p.m., Central Time today to discuss
the information contained in this press release. The live web cast may be accessed on the
investor relations portion of our web site at www.vascularsolutions.com. Web
participants are encouraged to go to the web site at least 15 minutes prior to the start
of the call to download and install any necessary audio software. An audio replay of the
call will be available until Thursday, February 9th by dialing 1-800-642-1687
and entering conference ID #4315524. A recording of the call will also be archived on the
investor relations portion of the Companys web site,
www.vascularsolutions.com until Thursday, February 9th. During the
conference call the Company may answer one or more questions concerning business and
financial developments and trends, the Companys view on earnings forecasts and new
product development and financial matters affecting the Company, some of the responses to
which may contain information that has not been previously disclosed.

---

VASCULAR SOLUTIONS, INC.
CONDENSED STATEMENTS OF OPERATIONS

|(In thousands, except per share data) |  | Three Months Ended |   | Twelve Months Ended
|------------------------------------- |  | ------------------ | - | -------------------
|
|
|
|                                     
|Net sales                             |  |                    | $ | 8,859              
|Cost of goods sold                    |  |                    |   | 2,690              
|                                      |  |                    |   |                    
|Gross profit                          |  |                    |   | 6,169              
|                                     
|Operating expenses:                   |  |                   
|Research and development              |  |                    |   | 1,079              
|Clinical and regulatory               |  |                    |   | 473                
|Sales and marketing                   |  |                    |   | 3,645              
|General and administrative            |  |                    |   | 805                
|Thrombin qualification                |  |                    |   | 563                
|Amortization of purchased             |  |                    |   | 54                 
|technology                            |  |                   
|                                      |  |                    |   |                    
|Operating loss                        |  |                    |   | (450               
|Interest income                       |  |                    |   | 43                 
|                                      |  |                    |   |                    
|Net loss                              |  |                    | $ | (407               
|                                      |  |                    |   |                    
|Net loss per share - basic            |  |                    | $ | (0.03              
|                                      |  |                    |   |                    
|Weighted average shares used in       |  |                   
|calculating - basic                   |  |                    |   | 14,627             
|                                      |  |                    |   |                    
|Net loss per share - diluted          |  |                    | $ | (0.03              
|                                      |  |                    |   |                    
|Weighted average shares used in       |  |                   
|calculating - diluted                 |  |                    |   | 14,627             
|                                      |  |                    |   |                    

---

VASCULAR SOLUTIONS, INC.CONDENSED BALANCE
SHEETS

|                                           | December 31,
2005
(note) |  | December 31,
2004
(note)
|------------------------------------------ | ------------------------ |  | ------------------------
|ASSETS                                     |                          |  |                         
|Current assets:                            |                          | 
|Cash and cash equivalents                  |                          |  | $                       
|Accounts receivable, net                   |                          |  |                         
|Inventories                                |                          |  |                         
|Prepaid expenses                           |                          |  |                         
|                                           |                          |  |                         
|Total current assets                       |                          |  |                         
|Property and equipment, net                |                          |  |                         
|Intangible assets                          |                          |  |                         
|                                           |                          |  |                         
|Total assets                               |                          |  | $                       
|                                           |                          |  |                         
|LIABILITIES AND SHAREHOLDERS EQUITY       |                          | 
|Current liabilities:                       |                          | 
|Total current liabilities                  |                          |  | $                       
|Shareholders equity:                      |                          | 
|Total shareholders equity                 |                          |  |                         
|                                           |                          |  |                         
|Total liabilities and shareholders equity |                          |  | $                       
|                                           |                          |  |                         

Note: Derived from the audited
financial statements at that date.

# Use of Non-GAAP Measures

Management
uses non-GAAP measures to establish operational goals, and believes that non-GAAP measures
may assist investors in analyzing the underlying trends in the Companys business
over time. Investors should consider these non-GAAP measures in addition to, not as a
substitute for or as superior to, financial reporting measures prepared in accordance with
GAAP. In this press release, the Company has reported a non-GAAP measure called adjusted
net income which excludes certain expenses relating to the qualification of a new supply
of thrombin as well as taxes net income using a 40% tax rate. On October 18, 2004, the
Company entered into a supply agreement with Sigma-Aldrich Fine Chemicals for the
development, manufacture and supply of bulk thrombin for use in the Companys
hemostatic products. The Company estimates that the development and qualification of this
new supply of thrombin will take approximately two years to complete, with estimated
expenditures through the end of 2006 expected to be approximately $4.3 million in
operating expenses, $1.7 million in inventory and $0.8 million in capital equipment
purchases. The Company has incurred approximately $1.8 million of the operating expenses,
$1.7 million of the inventory expenses and $0.7 million of the capital expenditures
through December 31, 2005. Management believes that although the qualification expenses
are a recurring cost it is useful to exclude them from net income given the short duration
of these expenses and the expectation that similar expenses will not need to be incurred
for the foreseeable future. Management uses the adjusted net income measure in its
internal analysis and review of operational performance. Management includes the thrombin
qualification expenses as well as the related inventory and capital equipment purchases in
its cash projections. Management believes that this adjusted net income measure provides
investors with useful information in comparing the Companys performance over
different periods, particularly when comparing this period to periods in which the Company
did not incur any expenses relating to the qualification of its new thrombin supply. By
using this non-GAAP measure management believes that investors get a better picture of the
performance of the Companys underlying business. Management encourages investors to
review the Companys net income prepared in accordance with GAAP to understand the
Companys performance taking into account all relevant factors, including those that
may only occur from time to time but have a material impact on the Companys
financial results.

---

# About Vascular Solutions

Vascular
Solutions, Inc. is a medical device company that focuses on developing unique solutions
for unmet clinical opportunities within Interventional radiology and Interventional
cardiology. New products introduced since the second half of 2003 include the
Vari-Lase® endovenous laser product line for the treatment of varicose veins, the
D-Stat Dry hemostatic bandage for the rapid control of topical bleeding, the
Pronto extraction catheter for the mechanical extraction of soft thrombus and the
Langston® dual lumen catheter for the measurement of aortic stenosis. The
Companys other major products include the Duett sealing device to rapidly seal
the puncture site following catheterization procedures and the D-Stat® Flowable
hemostat for the local management of active bleeding.

The
information in this press release contains forward-looking statements that involve risks
and uncertainties. Our actual results could differ materially from those anticipated in
these forward-looking statements. Important factors that may cause such differences
include those discussed in our Annual Report on Form 10-K for the year ended December 31,
2004 and other recent filings with the Securities and Exchange Commission. The risks and
uncertainties include, without limitation, risks associated with the need for adoption of
our new products, limited working capital, lack of profitability, exposure to intellectual
property claims, dependence on key vendors, exposure to possible product liability claims,
the development of new products by others, doing business in international markets,
limited manufacturing experience, the availability of third party reimbursement, and
actions by the FDA.

For
further information, connect to www.vascularsolutions.com.

# # #